Cardiac Allograft Vasculopathy in Heart Transplant Patients. Pathologic and Clinical Aspects for Angioplasty/Stenting* * Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.

Journal of the American College of Cardiology

Volumn 48, Issue 3, 2006, Pages 462-463

  Kobashigawa, Jon A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN;

ANGIOPLASTY; ATHEROSCLEROSIS; CARDIAC ALLOGRAFT VASCULOPATHY; CLINICAL FEATURE; CONVENTIONAL ANGIOGRAPHY; DISEASE COURSE; EDITORIAL; FOLLOW UP; HEART TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; INTRAVASCULAR ULTRASOUND; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESTENOSIS; RETRANSPLANTATION; RISK ASSESSMENT; RISK FACTOR; SURVIVAL TIME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY DISEASE; HEART TRANSPLANTATION; HUMANS; STENTS;

EID: 33746208052     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.05.003     Document Type: Editorial

References (10)

1. Jonas M., Fang J.C., Wang J.C., et al. In-stent restenosis and remote coronary lesion progression are coupled in cardiac transplant vasculopathy but not in native coronary artery disease. J Am Coll Cardiol 48 (2006) 453-461
2. Kobashigawa J., Wener L., Johnson J., et al. Longitudinal study of vascular remodeling in coronary arteries after heart transplantation. J Heart Lung Transplant 19 (2000) 546-550
3. Kobashigawa J.A., Tobis J.M., Starling R.C., et al. Multicenter intravascular ultrasound validation study among heart transplant recipients. outcomes after five years. J Am Coll Cardiol 45 (2005) 1532-1537
4. Keogh A., Richardson M., Ruygrok P., et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years. a randomized clinical trial. Circulation 110 (2004) 2694-2700
5. Eisen H.J., Tuzcu E.M., Dorent R., et al., RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients. N Engl J Med 349 (2003) 847-858
6. Kobashigawa J.A., Tobis J.M., Mentzer R.M., et al. Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplantation. reanalysis of the multicenter trial. Am J Transplant 6 (2006) 993-997
7. Kapadia S.R., Nissen S.E., Ziada K.M., et al. Impact of lipid abnormalities in development and progression of transplant coronary disease. a serial intravascular ultrasound study. J Am Coll Cardiol 38 (2001) 206-213
8. Kobashigawa J.A., Katznelson S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333 (1995) 621-627
9. Kobashigawa J.A. Statins in solid organ transplantation. is there an immunosuppressive effect?. Am J Transplant 4 (2004) 1013-1018
10. Hognestad A., Endresen K., Wergeland R., et al. Plasma C-reactive protein as a marker of cardiac allograft vasculopathy in heart transplant recipients. J Am Coll Cardiol 42 (2003) 477-482